Pseudohermaphrodites:
Pseudohermaphrodites, the term used for an individual
with gonads and genotype of one sex and external genitalia of the
opposite sex.
Female
Pseudohermaphrodites:
Patients with
female pseudohermaphroditism have female internal genitalia and
46XX karyotype
together with various degree of external genitalia virilization.
External genitalia
is musculinized congenitally when female fetus is exposed to excess
androgenic environment.
Congenital adrenal
hyperplasia (CAH), mostly 21-hydroxylase deficiency, is the most common
cause.
Maternal androgen
excess due to maternal ovarian tumour or drug intake also causes female
pseudohermaphroditism.
Combination of
hormonal therapy and surgical correction is required for CAH. When
appropriate treatments are given, normal puberty, fertility and child
bearing are possible.
HLA typing in
patient's family is useful for identifying heterozygote and homozygote,
because of close linkage of 21-hydroxylase gene and HLA gene.
Prenatal diagnosis
and genetic diagnosis for female pseudohermaphroditism due to
21-hydroxylase deficiency can be performed, however prenatal treatment
is not completely established.
|
Psychosexual development in individuals who have female
pseudohermaphroditism.Child
Adolesc Psychiatr Clin N Am. 2004 Jul;13(3):641-56.
This article
describes psychosexual outcomes and issues in syndromes of female
pseudohermaphroditism, broadly defined. Congenital adrenal
hyperplasia, the most common cause of intersex genitalia at birth,
is covered as are Turner Syndrome and syndromes in which XY infants
who are born with undervirilized genitalia are assigned and reared
as girls (androgen insensitivity syndrome; cloacal exstrophy). The
same hormonal abnormalities that cause most physical intersex
conditions also influence brain development and behavior;
individuals who have intersex conditions can show behavior that is
in between that of the typical boy/man and the typical girl/woman.
Changes in sex-typical play behavior in childhood are larger than in
sexual orientation or core gender identity in adulthood. Most female
pseudohermaphrodites, whether XX or XY, who are assigned and reared
as girls evolve a feminine core gender identity and primarily are
heterosexual. Implications for current debate about the treatment of
infants who have ambiguous genitalia are discussed, as is the need
for additional research and for consideration of psychologic
counseling as part of the treatment program.
Feminine pseudo-hermaphroditism
and ovarian polycystic syndrome: the role of hydrocortisone.Gynecol
Obstet Fertil. 2002 Jun;30(6):498-502.
We report the
case of a patient who was initially assigned as a male, and in whom
the diagnosis of CAH was delayed (17 years of age). He was shown to
have female pseudohermaphrodites. Before treatment, plasma
testosterone level was: 15 ng/mL (N: 0.1-0.7), 17 OH progesterone
(17 OHP): 45 ng/mL (N: 0.1-1.1) and FSH, LH values were below the
normal range. While taking hydrocortisone, a rapid onset of new
clinical, biological and radiological findings were observed after
three months: rapid menarche and thelarche occurred, plasma
testosterone and 17 OHP levels decreased, respectively 1 and 3.7 ng/mL,
plasma FSH and LH were respectively 4.1 mUI/mL (N: 1.5-7) and 14.3 m
UI/mL (N: 1.1-11.7). Polycystic ovaries were shown at sonography.
Authors try to discuss the mechanism of the new events observed and
specially those related to the polycystic ovarian disease. In a
female with untreated CAH at adult age, menarche can rapidly occur
once appropriate treatment was started.
Rare forms of female pseudohermaphroditism: when to investigate.
Arq Bras Endocrinol Metabol. 2005 Feb;49(1):126-37. Epub 2006
Mar 16.
The congenital
adrenal hyperplasia is the commonest cause of ambiguity of the
external genitalia at birth, due to classic forms of 21-hydroxylase
and 11beta-hydroxylase deficiencies. 3beta-hydroxysteroid
dehydrogenase (3betaHSD) is a rare disorder that affects both sexes
and female patients may have ambiguous genitalia. Familial
glucocorticoid resistance is characterized by increased cortisol
secretion without clinical evidence of hypercortisolism, but with
manifestations of androgen and mineralocorticoid excess, caused by
glucocorticoid receptor gene mutation, and rarely can lead to female
pseudohermaphroditism. Placental aromatase deficiency is a rare
disease characterized by a masculinized female fetus and a virilized
mother, which should be considered in the absence of fetal adrenal
hyperplasia and maternal androgen-secreting tumours. Finally,
mutations of P450 oxidoreductase causes disordered steroidogenesis
with ambiguous genitalia. The investigation of abnormal sexual
development requires an initial karyotype analysis and serum 17OH
progesterone, 11 deoxycortisol, 17 pregnenolone, and androgen
measurements to assess the diagnosis of different forms of
congenital adrenal hyperplasia. |
Male
Pseudohermaphrodites:
Y chromosome is present, and hence the gonads are
exclusively testes, but external genitalia are either ambiguous or
completely female.
The condition results from defective virilization of
the male embryo due to reduced androgen synthesis or resistance of
action of androgens.
The most common form is
complete
testicular feminization associated with mutation in
the structural gene for androgen receptor located
on Xq11-Xq12.
|
17beta-hydroxysteroid dehydrogenase 3 deficiency in a male
pseudohermaphrodite.
Fertil Steril. 2008 Jan;89(1):228.e13-7.
OBJECTIVE: To
present the clinical, biochemical, and genetic features of a male
pseudohermaphrodite whose condition was caused by
17beta-hydroxysteroid dehydrogenase 3 (17beta-HSD3) deficiency.
DESIGN: Case report. SETTING: Gynecology practice in a university
teaching hospital. PATIENT(S): A 15-year-old black American male
pseudohermaphrodite with 17beta-HSD3 deficiency. INTERVENTION(S):
Laboratory evaluation, genetic mutation analysis, bilateral
gonadectomy, and hormone replacement. MAIN OUTCOME MEASURE(S):
Endocrinologic evaluation and genetic analysis. RESULT(S): A
diagnosis of 17beta-HSD3 deficiency made on the basis of hormone
evaluation was confirmed through genetic mutation analysis of the
HSD17B3 gene. Female phenotype was attained after gonadectomy,
passive vaginal dilatation, and hormone therapy. CONCLUSION(S):
Deficiency of 17beta-HSD3 was diagnosed in this patient on the basis
of endocrinologic evaluation and was confirmed with genetic mutation
analysis. The patient was able to retain her female sexual identity
after surgical and medical treatment.
Study of a new case of male pseudohermaphroditism due to
17-ketosteroid reductase deficiency (author's transl). Ann
Endocrinol (Paris). 1979;40(6):549-50.
We studied a 17
year old patient with primary amenorrhea, hirsutixm, clitoral
enlargment, poor breast development and 46, XY karyotype. The
results shown in table clearly indicate a 17-ketosteroid reductase
deficiency. In the view of previously described patients we can
conclude that: 1) intensity of virilisation depends on both plasma
testosterone and androstenedione levels; 2) importance of
gynecomastia depends on plasma E2 but not E1 levels; 3) FSH levels
are not correlated with circulating androgens or estrogens but
presumably depends on importance of seminiferous tubules' lesions.
Male pseudohermaphroditism with gynaecomastia due to testicular
17-ketosteroid reductase deficiency. Clin
Endocrinol (Oxf). 1977 Dec;7(6):443-52.
A 28-year-old
male pseudohermaphrodite with gynaecomastia was raised as a female
until the age of 17 years, at which time he developed masculine
features (deepening of the voice, development of facial hair, male
distribution of body hair and male body habitus) and assumed a male
gender role. He had a small phallus with perineal urethra, absence
of labioscrotal fusion, presence of vaginal pouch and undescended
testes. The testicular biopsy showed hyalinization of the tubular
basement membrane, lack of spermatogenesis and hyperplastic Leydig
cells. Baseline peripheral plasma studies showed androstenedione
concentrations ten times normal, low testosterone, elevated oestrone
and elevated gonadotrophins. The in vitro incubation of testicular
tissue showed no significant conversion of androstenedione to
testosterone. However, two types of peripheral tissues, skin
fibroblasts and erythrocytes, had a normal conversion, as did the
body overall as measured by the technique of androstenedione
constant infusion. These studies demonstrate that the 17-ketosteroid
reductase deficiency of the patient was limited to the testes.
|
Contents

|